MGX Stock Overview
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Metagenomi, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.61 |
| 52 Week High | US$12.74 |
| 52 Week Low | US$1.61 |
| Beta | 0 |
| 1 Month Change | -16.08% |
| 3 Month Change | 33.16% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.68% |
Recent News & Updates
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
Jan 14
Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry
Dec 10Shareholder Returns
| MGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.6% | -0.2% | 3.2% |
| 1Y | n/a | -6.9% | 24.0% |
Return vs Industry: Insufficient data to determine how MGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MGX performed against the US Market.
Price Volatility
| MGX volatility | |
|---|---|
| MGX Average Weekly Movement | 38.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGX's weekly volatility has increased from 22% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 207 | Brian Thomas | www.metagenomi.co |
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
Metagenomi, Inc. Fundamentals Summary
| MGX fundamental statistics | |
|---|---|
| Market cap | US$103.66m |
| Earnings (TTM) | -US$73.95m |
| Revenue (TTM) | US$55.08m |
1.8x
P/S Ratio-1.3x
P/E RatioIs MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGX income statement (TTM) | |
|---|---|
| Revenue | US$55.08m |
| Cost of Revenue | US$110.77m |
| Gross Profit | -US$55.69m |
| Other Expenses | US$18.26m |
| Earnings | -US$73.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | -101.11% |
| Net Profit Margin | -134.27% |
| Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 23:50 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Metagenomi, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |